Topic Review
Multi-Omic Blood Biomarkers in Late-Onset Alzheimer’s Disease
Late-onset Alzheimer’s disease is the leading cause of dementia worldwide, accounting for a growing burden of morbidity and mortality. Diagnosing Alzheimer’s disease before symptoms are established is clinically challenging, but would provide therapeutic windows for disease-modifying interventions. Blood biomarkers, including genetics, proteins and metabolites, are emerging as powerful predictors of Alzheimer’s disease at various timepoints within the disease course, including at the preclinical stage.
  • 556
  • 08 Feb 2024
Topic Review
Biological Drugs in EoE and Their Targets
Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms involved in the pathogenesis of EoE and biologics, in particular monoclonal antibodies (mAbs), targeting these pathways are needed. Currently, the most relevant is dupilumab, which interferes with both interleukin (IL)-4 and IL-13 pathways by binding IL-4 receptor α, and is the only mAb approved by the European Medicine Agency and US Food and Drug Administration for the treatment of EoE. Other mAbs investigated include mepolizumab, reslizumab, and benralizumab (interfering with IL-5 axis), cendakimab and dectrekumab (anti-IL-13s), tezepelumab (anti-TSLP), lirentelimab (anti-SIGLEG-8), and many others.
  • 120
  • 08 Feb 2024
Topic Review
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders
One of the most common subgroups of cutaneous T-cell lymphomas is that of primary cutaneous CD30-positive lymphoproliferative disorders. The group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL), as well as some borderline cases. Significant progress has been made in understanding the genetics and treatment of these disorders. 
  • 227
  • 08 Feb 2024
Topic Review
PI3K/AKT/mTOR and MAPK Pathways in Gastric Cancer
Gastric cancer (GC) is the fourth leading cause of death worldwide, with more than 1 million cases diagnosed every year. Helicobacter pylori represents the main risk factor, being responsible for 78% of the cases. Increased amounts of salt, pickled food, red meat, alcohol, smoked food, and refined sugars negatively affect the stomach wall, contributing to GC development.
  • 331
  • 08 Feb 2024
Topic Review
Protease Inhibitors as Antivirals
Viral proteases play a key role in viral replication for all positive single-stranded RNA viruses and some DNA viruses, such as herpesviruses. To treat infections caused by these viruses, proteases are considered excellent drug targets. Protease inhibitors are now routinely used in antiviral therapy for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections. Since SARS-CoV-2 Mpro plays a key role in viral replication by cleaving viral polyproteins, inhibition of its catalytic activity represents an attractive therapeutic approach for the treatment of COVID-19.
  • 195
  • 08 Feb 2024
Topic Review
Parvovirus B19 Infection and Pregnancy
Parvovirus B19, a member of the Parvoviridae family, is a human pathogenic virus. It can be transmitted by respiratory secretions, hand-to-mouth contact, blood transfusion, or transplacental transmission. Most patients are asymptomatic or present with mild symptoms such as erythema infectiosum, especially in children. In rare cases, moderate-to-severe symptoms may occur, affecting blood cells and other systems, resulting in anemia, thrombocytopenia, and neutropenia. Non-immune pregnant women are at risk for fetal infection by parvovirus B19, with greater complications if transmission occurs in the first or second trimester. Infected fetuses may not show any abnormalities in most cases, but in more severe cases, there may be severe fetal anemia, hydrops, and even pregnancy loss. 
  • 207
  • 08 Feb 2024
Topic Review
Oral Selective Estrogen Receptor Degraders in Development
Breast cancer is a common type of cancer among women. One type, estrogen receptor-positive (ER+), is treated with endocrine therapies. However, some patients develop resistance to these therapies, which is a challenge. Scientists have developed second-generation drugs called selective estrogen receptor degraders (SERDs) that can overcome the limitations of the existing treatment.
  • 467
  • 08 Feb 2024
Topic Review
Modification of Preservative Fluids with Antioxidants
Transplantation is currently the only effective treatment for patients with end-stage liver failure. Many advanced studies have been conducted to improve the efficiency of organ preservation techniques. Modifying the composition of the preservation fluids currently used may improve graft function and increase the likelihood of transplantation success. The modified fluid is expected to extend the period of safe liver storage in the peri-transplantation period and to increase the pool of organs for transplantation with livers from marginal donors. 
  • 88
  • 08 Feb 2024
Topic Review
CytoSorb® Hemoadsorption Therapy in Patients with Infective Endocarditis
Infective endocarditis (IE) is a rare but severe disease with high morbidity and mortality. Cardiac surgery plays a major role in the contemporary clinical management of IE patients.
  • 89
  • 08 Feb 2024
Topic Review
The Useful Antiviral Properties of Lysozyme
Lysozyme, especially the one obtained from hen’s egg white, continues to show new pharmacological properties. Lysozyme can interact with nucleic acids and alter their function, but this effect is uncoupled from the catalytic activity that determines its antibacterial activity; it is present in intact lysozyme but is equally potent in a heat-degraded lysozyme or in a nonapeptide isolated by proteolytic digestion.
  • 350
  • 08 Feb 2024
  • Page
  • of
  • 1352
Video Production Service